使用费鲁莫托醇MRI和Macrin检测靶向PDL1和BRAF治疗在未分化甲状腺癌中的免疫反应
在未分化甲状腺癌小鼠模型中,费鲁莫托醇增强MRI显示原位甲状腺肿瘤摄取较肺转移灶高136%±88,反映肿瘤相关巨噬细胞浸润和血管化差异;BRAF抑制剂联合抗PDL1抗体使肺部肿瘤的治疗纳米颗粒递送增加39%±14,但联合CSF1R阻断抗体未进一步增加肿瘤相关巨噬细胞或纳米颗粒水平。
要点
- 费鲁莫托醇MRI可无创评估未分化甲状腺癌肿瘤相关巨噬细胞浸润和血管化。
- 原位甲状腺肿瘤的巨噬细胞水平和费鲁莫托醇摄取均高于肺转移灶。
- BRAF抑制剂联合抗PDL1抗体可提高肺部肿瘤的治疗纳米颗粒递送。
核心结论
- 在未分化甲状腺癌小鼠模型中,费鲁莫托醇MRI显示原位甲状腺肿瘤摄取较肺部病灶高136%±88,反映高血管化和较高肿瘤相关巨噬细胞水平。
- BRAF抑制剂和抗PDL1抗体引起肺部肿瘤局部肿瘤相关巨噬细胞水平升高和治疗纳米颗粒递送增加43%±20,但血管化未升高。
研究设计与样本
- 研究为前瞻性动物实验,在6-8周龄雌性B6129SF1/J小鼠中经甲状腺内注射建立原位未分化甲状腺癌模型或经静脉注射建立血行转移模型,于2018年8月1日至2020年1月15日随机纳入治疗队列,共94只。
- 小鼠接受溶媒或BRAF激酶抑制剂联合抗PDL1抗体治疗,部分联合约70 nm模型药物递送纳米颗粒和抗CSF1R中和抗体。
- 使用基因工程BrafV600E/WT p53缺失同种异体移植物,并补充GFP转基因衍生株和人异种移植;荷瘤器官经组织透明化后行共聚焦显微镜和MRI检查。
- 影像检查包括宏观费鲁莫托醇-MRI和微观Macrin。
- 比较采用双尾Wilcoxon检验,每组至少5只。
关键影像表现/征象
- 原位甲状腺肿瘤的肿瘤相关巨噬细胞水平较肺部转移灶高79%±23(标准差;P < .001)。
- 费鲁莫托醇MRI显示甲状腺病灶摄取较肺部病灶高136%±88(P = .02),与肿瘤相关巨噬细胞水平一致。
- BRAF抑制剂联合抗PDL1抗体治疗后,肺部病灶的治疗纳米颗粒递送较对照升高39%±14(P = .004)。
- 与未治疗组相比,BRAF抑制剂、抗PDL1抗体和CSF1R阻断抗体联合治疗后肿瘤相关巨噬细胞或纳米颗粒水平无显著差异(P = .82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive microenvironment created by tumor-associated macrophages (TAMs). Purpose To understand the relationship between TAM infiltration, tumor vascularization, and corresponding drug delivery by using ferumoxytol-enhanced MRI and macrin in an ATC mouse model. Materials and Methods ATC tumors were generated in 6-8-week-old female B6129SF1/J mice through intrathyroid injection to model orthotopic tumors, or intravenously to model hematogenous metastasis, and prospectively enrolled randomly into treatment cohorts (n = 94 total; August 1, 2018, to January 15, 2020). Mice were treated with vehicle or combined serine/threonine-protein kinase B-Raf (BRAF) kinase inhibitor (BRAFi) and anti-PDL1 antibody (aPDL1). A subset was cotreated with therapies, including an approximately 70-nm model drug delivery nanoparticle (DDNP) to target TAM, and an antibody-neutralizing colony stimulating factor 1 receptor (CSF1R). Imaging was performed at the macroscopic level with ferumoxytol-MRI and microscopically with macrin. Genetically engineered BrafV600E/WT p53-null allografts were used and complemented by a GFP-transgenic derivative and human xenografts. Tumor-bearing organs were processed by using tissue clearing and imaged with confocal microscopy and MRI. Two-tailed Wilcoxon tests were used for comparison (≥five per group). Results TAM levels were higher in orthotopic thyroid tumors compared with pulmonary metastatic lesions by 79% ± 23 (standard deviation; P < .001). These findings were concordant with ferumoxytol MRI, which showed 136% ± 88 higher uptake in thyroid lesions (P = .02) compared with lung lesions. BRAFi and aPDL1 combination therapy resulted in higher tumor DDNP delivery by 39% ± 14 in pulmonary lesions (P = .004). Compared with the untreated group, tumors following BRAFi, aPDL1, and CSF1R-blocking antibody combination therapy did not show greater levels of TAM or DDNP (P = .82). Conclusion In a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% ± 88 greater uptake in orthotopic thyroid tumors compared with pulmonary lesions, which reflected high vascularization and greater tumor-associated macrophage (TAM) levels. Serine/threonine-protein kinase B-Raf inhibitor and anti-programmed death ligand 1 antibody elicited higher local TAM levels and 43% ± 20 greater therapeutic nanoparticle delivery but not higher vascularization in pulmonary tumors. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Luker in this issue.
引用
- Ng TSC, Gunda V, Li R, et al. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer. Radiology. 2020. PMID: 33107799. doi:10.1148/radiol.2020201791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。